Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15115MR)

This product GTTS-WQ15115MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15115MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10706MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ12593MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ7654MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ11785MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ11979MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ7643MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ9446MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ10479MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW